SAFETY DATA SHEET

Levamisole Formulation

SECTION 1. IDENTIFICATION

Product name : Levamisole Formulation

Manufacturer or supplier's details
Company name of supplier : Merck & Co., Inc
Address : 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use
Recommended use : Veterinary product
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)
Combustible dust

Acute toxicity (Oral) : Category 4
Reproductive toxicity : Category 2
Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Blood, Testis)

GHS label elements
Hazard pictograms :

Signal Word : Warning

Hazard Statements : If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air.
H302 Harmful if swallowed.
H361d Suspected of damaging the unborn child.
H373 May cause damage to organs (Blood, Testis) through prolonged or repeated exposure if swallowed.

Precautionary Statements :
Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves, protective clothing, eye protection and face protection.

Response:
P301 + P312 + P330 IF SWALLOWED: Call a doctor if you feel unwell. Rinse mouth.
P308 + P313 IF exposed or concerned: Get medical attention.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>:</th>
<th>Mixture</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Components</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical name</td>
<td>CAS-No.</td>
<td>Concentration (% w/w)</td>
</tr>
<tr>
<td>Levamisole hydrochloride</td>
<td>16595-80-5</td>
<td>15</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and delayed : Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.
Harmful if swallowed.
Suspected of damaging the unborn child.
SAFETY DATA SHEET

Levamisole Formulation

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during fire fighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters: In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions: Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling:
- Do not breathe dust.
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Wash skin thoroughly after handling.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Minimize dust generation and accumulation.
- Keep container closed when not in use.
- Keep away from heat and sources of ignition.
- Take precautionary measures against static discharges.
- Do not eat, drink or smoke when using this product.
- Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage:
- Keep in properly labeled containers.
- Store locked up.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types: Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Inert or nuisance dust</th>
<th>50 Million particles per cubic foot</th>
</tr>
</thead>
<tbody>
<tr>
<td>Value type (Form of exposure): TWA (total dust)</td>
<td>Basis: OSHA Z-3</td>
</tr>
<tr>
<td>15 mg/m³</td>
<td>Value type (Form of exposure): TWA (total dust)</td>
</tr>
<tr>
<td>5 mg/m³</td>
<td>Value type (Form of exposure): TWA (respirable fraction)</td>
</tr>
<tr>
<td>15 Million particles per cubic foot</td>
<td>Value type (Form of exposure): TWA (respirable fraction)</td>
</tr>
</tbody>
</table>

Dust, nuisance dust and particulates

| 10 mg/m³ | Value type (Form of exposure): PEL (Total dust) | Basis: CAL PEL |
SAFETY DATA SHEET
Levamisole Formulation

Version 2.0   Revision Date: 04/04/2023   SDS Number: 9081924-00005   Date of last issue: 10/01/2022
Date of first issue: 07/21/2021

5 mg/m³
Value type (Form of exposure): PEL (respirable dust fraction)
Basis: CAL PEL

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levamisole hydrochloride</td>
<td>16595-80-5</td>
<td>TWA</td>
<td>20 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Further information: Skin
Wipe limit 200 µg/100 cm² Internal

Engineering measures:
- Ensure adequate ventilation, especially in confined areas.
- Minimize workplace exposure concentrations.
- Apply measures to prevent dust explosions.
- Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment
Respiratory protection:
- General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection
- Material: Chemical-resistant gloves
- Remarks: Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Eye protection:
- Wear the following personal protective equipment: Safety goggles

Skin and body protection:
- Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.
- Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

Hygiene measures:
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
- When using do not eat, drink or smoke.
SAFETY DATA SHEET
Levamisole Formulation

Wash contaminated clothing before re-use.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder
Color : white
Odor : No data available
Odor Threshold : No data available
pH : No data available
Melting point/freezing point : No data available
Initial boiling point and boiling range : No data available
Flash point : Not applicable
Evaporation rate : Not applicable
Flammability (solid, gas) : May form combustible dust concentrations in air during processing, handling or other means.
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
Vapor pressure : Not applicable
Relative vapor density : Not applicable
Relative density : No data available
Density : No data available
Solubility(ies)
  Water solubility : No data available
Partition coefficient: n-octanol/water
Autoignition temperature : No data available
Decomposition temperature : No data available
Viscosity
  Viscosity, kinematic : Not applicable
Explosive properties : Not explosive
SAFETY DATA SHEET

Levamisole Formulation

Oxidizing properties: The substance or mixture is not classified as oxidizing.

Molecular weight: No data available

Particle size: No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: May form combustible dust concentrations in air during processing, handling or other means. Can react with strong oxidizing agents.

Conditions to avoid: Heat, flames and sparks.
 Avoid dust formation.

Incompatible materials: Oxidizing agents

Hazardous decomposition products: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Harmful if swallowed.

Product:
Acute oral toxicity: Acute toxicity estimate: 1,200 mg/kg
Method: Calculation method

Components:

Levamisole hydrochloride:

Acute oral toxicity: LD50 (Rat): 180 mg/kg
LD50 (Mouse): 223 mg/kg
LD50 (Rabbit): 458 mg/kg

Acute inhalation toxicity: Remarks: No data available

Acute dermal toxicity: Remarks: No data available

Skin corrosion/irritation
Not classified based on available information.
SAFETY DATA SHEET
Levamisole Formulation

Components:
Levamisole hydrochloride:
Remarks : No data available

Serious eye damage/eye irritation
Not classified based on available information.

Components:
Levamisole hydrochloride:
Remarks : No data available

Respiratory or skin sensitization
Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.

Components:
Levamisole hydrochloride:
Remarks : No data available

Germ cell mutagenicity
Not classified based on available information.

Components:
Levamisole hydrochloride:
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Carcinogenicity
Not classified based on available information.

Components:
Levamisole hydrochloride:
Species : Mouse
Application Route : Oral
Exposure time : 2 Years
NOAEL : 80 mg/kg body weight
Remarks : No significant adverse effects were reported

Species : Rat
Application Route : Oral
Exposure time : 2 Years
NOAEL : 40 mg/kg body weight
### Remarks

No significant adverse effects were reported.

**IARC**
No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA**
No component of this product present at levels greater than or equal to 0.1% is on OSHA’s list of regulated carcinogens.

**NTP**
No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

### Reproductive toxicity
Suspected of damaging the unborn child.

#### Components:

**Levamisole hydrochloride:**

<table>
<thead>
<tr>
<th>Effects on fertility</th>
<th>Test Type: Three-generation reproduction toxicity study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Species: Rat</td>
</tr>
<tr>
<td></td>
<td>Application Route: Oral</td>
</tr>
<tr>
<td></td>
<td>Result: No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Effects on fetal development</th>
<th>Test Type: Embry-o-fetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Species: Rat</td>
</tr>
<tr>
<td></td>
<td>Application Route: Oral</td>
</tr>
<tr>
<td></td>
<td>Developmental Toxicity: NOAEL: 20 mg/kg body weight</td>
</tr>
<tr>
<td></td>
<td>Result: Fetotoxicity.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type: Embry-o-fetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rabbit</td>
</tr>
<tr>
<td>Application Route: Oral</td>
</tr>
<tr>
<td>Developmental Toxicity: LOAEL: 40 mg/kg body weight</td>
</tr>
<tr>
<td>Result: Fetotoxicity.</td>
</tr>
</tbody>
</table>

**Reproductive toxicity - Assessment:** Some evidence of adverse effects on development, based on animal experiments.

### STOT-single exposure
Not classified based on available information.

### STOT-repeated exposure
May cause damage to organs (Blood, Testis) through prolonged or repeated exposure if swallowed.

#### Components:

**Levamisole hydrochloride:**

<table>
<thead>
<tr>
<th>Target Organs</th>
<th>Blood, Testis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assessment</td>
<td>May cause damage to organs through prolonged or repeated exposure.</td>
</tr>
</tbody>
</table>
Repeated dose toxicity

**Components:**

**Levamisole hydrochloride:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>2.5 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>18 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Testis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>20 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>18 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Blood</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>40 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>3 Months</td>
</tr>
</tbody>
</table>

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

**Components:**

**Levamisole hydrochloride:**

| Ingestion | Symptoms: Nausea, Vomiting, Headache, Dizziness, Hypotension |

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

**Components:**

**Levamisole hydrochloride:**

<table>
<thead>
<tr>
<th>Toxicity to fish</th>
<th>LC50 (Oryzias latipes (Japanese medaka)): 37.3 mg/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure time</td>
<td>96 h</td>
</tr>
<tr>
<td>Method</td>
<td>OECD Test Guideline 203</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Toxicity to daphnia and other aquatic invertebrates</th>
<th>EC50 (Daphnia magna (Water flea)): 64 mg/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure time</td>
<td>48 h</td>
</tr>
<tr>
<td>Method</td>
<td>OECD Test Guideline 202</td>
</tr>
</tbody>
</table>

Persistence and degradability

No data available

Bioaccumulative potential

No data available
SAFETY DATA SHEET
Levamisole Formulation

Mobility in soil
No data available

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

<table>
<thead>
<tr>
<th>Waste from residues</th>
<th>Dispose of in accordance with local regulations. Do not dispose of waste into sewer.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contaminated packaging</td>
<td>Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.</td>
</tr>
</tbody>
</table>

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

49 CFR
Not regulated as a dangerous good

Special precautions for user
Not applicable

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity
This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity
This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity
This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards
Combustible dust
Acute toxicity (any route of exposure)
Reproductive toxicity
Specific target organ toxicity (single or repeated exposure)
SAFETY DATA SHEET

Levamisole Formulation

Version 2.0  Revision Date: 04/04/2023  SDS Number: 9081924-00005  Date of last issue: 10/01/2022  Date of first issue: 07/21/2021

SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations
Pennsylvania Right To Know
Lactose 63-42-3
Levamisole hydrochloride 16595-80-5

The ingredients of this product are reported in the following inventories:

SECTION 16. OTHER INFORMATION

Further information
NFPA 704:

<table>
<thead>
<tr>
<th>Flammability</th>
<th>Health</th>
<th>Instability</th>
<th>Special hazard</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

HMIS® IV:

<table>
<thead>
<tr>
<th>HEALTH</th>
<th>FLAMMABILITY</th>
<th>PHYSICAL HAZARD</th>
</tr>
</thead>
<tbody>
<tr>
<td>*</td>
<td>2</td>
<td>0</td>
</tr>
</tbody>
</table>

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations
CAL PEL : California permissible exposure limits for chemical contaminants (Title 8, Article 107)
OSHA Z-3 : USA. Occupational Exposure Limits (OSHA) - Table Z-3 Mineral Dusts
CAL PEL / PEL : Permissible exposure limit
OSHA Z-3 / TWA : 8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with % response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with % response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with % growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -
International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative


Revision Date: 04/04/2023

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.